Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference
Generation Bio Co. (Nasdaq: GBIO) announced its participation in the virtual 2022 Wedbush PacGrow Healthcare Conference scheduled for August 9th at 9:45 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio Co. (Nasdaq: GBIO) announced its participation in the virtual 2022 Wedbush PacGrow Healthcare Conference scheduled for August 9th at 9:45 a.m. ET. The event will include a live webcast available on the company’s investor website, with a replay accessible for 30 days post-event. Generation Bio is focused on advancing genetic medicines using its unique non-viral platform, which aims to provide durable, redosable treatments for rare and prevalent diseases, utilizing innovative technologies like closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticles.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was +17.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.